Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Guggenheim Securities SMID Cap Biotech Conference.
Details are as follows:
Event: Guggenheim Securities SMID Cap Biotech ConferenceDate: Wednesday, February 5, 2025Time: 1:30 PM ET Format: Fireside chat Webcast: https://wsw.com/webcast/guggen2/cdtx/2014749
A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com. The replay of the presentation will be available for 90 days.
Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara at the conference should contact their Guggenheim representative directly.
About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com
MEDIA CONTACT:Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
17 minutes ago
- Associated Press
ABL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Abacus Global Management, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Abacus Global Management, Inc. (NASDAQ: ABL) focused on whether Abacus Global and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Abacus Global investigation or if you are an Abacus Global investor who suffered a loss and would like to learn more, you can provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. THE COMPANY: Abacus Global operates as an alternative asset manager and market maker. THE REVELATION: On June 4, 2025, Morpheus Research published a report titled 'Abacus Global Management: This $740 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue By Systematically Underestimating When People Will Die.' On this news, Abacus Global's stock price fell more than 21%. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Yahoo
23 minutes ago
- Yahoo
Qualcomm Bets $2.4 Billion On Alphawave To Power AI Data Centers
Qualcomm Inc (NASDAQ:QCOM) announced on Monday that it has agreed to acquire semiconductor company Alphawave IP Group Plc for approximately $2.4 billion in cash. The purchase price implies 183 pence per share for Alphawave, implying close to a 96% premium to the price immediately before Qualcomm disclosed its interest in the company. The acquisition of Alphawave Semi aims to further accelerate, and provide key assets for, Qualcomm's expansion into data centers. Qualcomm Oryon CPU and Hexagon NPU processors are well positioned to meet the growing demand for high-performance, low-power computing, which is being driven by a rapid increase in AI inferencing and the transition to custom CPUs in data centers, the company said in a press release. Also Read: The deal, subject to regulatory and shareholder approval, will likely close in the first quarter of 2026. Qualcomm held $13.85 billion in cash and equivalents as of March 31, 2025. In May, JP Morgan analyst Samik Chatterjee said Alphawave has higher strategic importance for Qualcomm, which has recently more explicitly outlined its intent to pursue the data center market as another pillar of growth and diversification. The analyst said Alphawave's acquisition and capabilities regarding data center connectivity IP would complement its earlier acquisition of Nuvia and its capabilities for designing data center CPUs and AI inference chips based on custom ARM cores. Chatterjee expects Alphawave's breadth of capabilities to add to Qualcomm's portfolio, positioning the company to benefit from tailwinds related to strong growth in Custom silicon and ASIC adoption within AI infrastructure and development in content about connectivity products within AI data centers. He added that Alphawave's immediate contribution to Qualcomm's financial performance is unlikely material, but the company expects synergies from its entry into the broader data center TAM. Price Action: QCOM stock is trading higher by 0.19% to $149.52 premarket at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? QUALCOMM (QCOM): Free Stock Analysis Report This article Qualcomm Bets $2.4 Billion On Alphawave To Power AI Data Centers originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Nutraceutical Excipients Global Strategic Business Report 2025-2030: Technological Innovations in Multi-Functional Excipients Propel Growth, Increasing Preference for Clean-Label and Natural Ingredients
The global Nutraceutical Excipients market is expected to grow from USD 5 billion in 2024 to USD 7.2 billion by 2030, at a CAGR of 6.2%. Key trends driving this market include a shift towards clean-label, organic excipients and technological advances like nanotechnology that enhance ingredient bioavailability. This report offers comprehensive insights into market trends, regional growth projections, and strategic opportunities, identifying major players such as ABF Ingredients and Cargill. Explore detailed regional analyses and future market insights to inform strategic decisions. Nutraceutical Excipients Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Nutraceutical Excipients - Global Strategic Business Report" report has been added to global market for Nutraceutical Excipients was valued at US$5.0 Billion in 2024 and is projected to reach US$7.2 Billion by 2030, growing at a CAGR of 6.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Nutraceutical excipients are inactive ingredients used in the production of nutraceutical products such as dietary supplements, functional foods, and fortified beverages. These excipients serve a crucial role by aiding in the stabilization, preservation, and delivery of active ingredients like vitamins, minerals, and bioactive compounds. Growth in the Nutraceutical Excipients Market Is Driven by Several FactorsGrowth in the nutraceutical excipients market is driven by several factors, including innovations in excipient technology, evolving consumer preferences, and increasing regulatory scrutiny. Advances in excipient formulations, such as the development of multifunctional and bioenhancing excipients, are expanding the range of nutraceutical products available to consumers. The growing popularity of clean-label and organic products is also fueling demand for natural excipients that meet consumer expectations for purity and safety. Additionally, the rise in chronic health conditions and aging populations is increasing the need for functional and targeted nutraceuticals, further driving demand for excipients that improve the bioavailability and stability of active ingredients. Regulatory requirements for product safety and quality are pushing manufacturers to innovate, ensuring excipients meet the highest standards for efficacy and safety. How Are Innovations in Nutraceutical Excipients Shaping the Market?Technological advancements in excipient development are driving significant changes in the nutraceutical market. The demand for excipients that are organic, non-GMO, and free from allergens is on the rise, reflecting consumer preferences for clean-label products. New innovations in multifunctional excipients, which can perform multiple roles such as improving both bioavailability and stability, are gaining traction. Additionally, advancements in nanotechnology are enabling the development of excipients that enhance the solubility and absorption of poorly soluble nutraceutical ingredients. These innovations are leading to the production of more effective, faster-acting, and longer-lasting nutraceutical products, appealing to consumers who prioritize both efficacy and natural Are Consumer Preferences and Regulatory Trends Impacting Demand for Nutraceutical Excipients?The growing focus on health and wellness has spurred consumer demand for nutraceutical products that are safe, effective, and free from artificial additives. This shift is influencing the nutraceutical excipients market, as manufacturers are increasingly opting for natural, organic, and clean-label excipients that align with consumer values. Regulatory bodies are also playing a key role by setting stringent guidelines for excipient safety and quality, particularly in regions like North America and Europe. As a result, excipient manufacturers are investing in research and development to create products that comply with these regulations while offering superior functionality. Moreover, the rise of personalized nutrition is driving demand for excipients that enable the production of customized nutraceutical solutions, expanding the market's Scope Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as ABF Ingredients, Cargill, Inc., Dow, Inc., DuPont de Nemours, Inc., EGGLE Wasserburg Verwaltungs GmbH and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Binders segment, which is expected to reach US$2.4 Billion by 2030 with a CAGR of a 7.6%. The Fillers & Diluents segment is also set to grow at 5.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.3 Billion in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $1.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments: Functionality (Binders, Fillers & Diluents, Coating Agents, Lubricants, Disintegrants, Flavoring Agents) Form (Dry, Liquid) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 308 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5 Billion Forecasted Market Value (USD) by 2030 $7.2 Billion Compound Annual Growth Rate 6.2% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update Nutraceutical Excipients - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Consumer Demand for Functional Foods and Dietary Supplements Drives Growth in Nutraceutical Excipients Market Technological Advancements in Drug Delivery Systems Propel the Adoption of Innovative Nutraceutical Excipients Increasing Preference for Clean-Label and Natural Ingredients Expands the Market for Organic Nutraceutical Excipients Growing Focus on Enhanced Bioavailability and Solubility Strengthens Demand for Advanced Excipient Formulations Rising Awareness of Preventative Healthcare and Wellness Fuels Growth in Nutraceutical Supplements, Driving Excipient Demand Technological Innovations in Multi-Functional Excipients Propel Growth in Nutraceutical Manufacturing Efficiency Increased Regulatory Scrutiny on Ingredient Safety and Quality Standards Spurs Demand for Compliant Excipients Growing Use of Probiotics and Prebiotics Expands Opportunities for Specialized Nutraceutical Excipients Consumer Trends Toward Sugar-Free and Low-Calorie Supplements Accelerate Demand for Sweetening and Flavoring Excipients Expansion of Sports Nutrition and Weight Management Products Throws the Spotlight on Performance-Enhancing Excipients Rising Popularity of Plant-Based and Vegan Nutraceuticals Strengthens the Business Case for Non-Animal Derived Excipients Growth in Elderly Population and Demand for Age-Related Supplements Propel Market Adoption of Digestive-Friendly Excipients FOCUS ON SELECT PLAYERS ABF Ingredients Cargill, Inc. Dow, Inc. DuPont de Nemours, Inc. EGGLE Wasserburg Verwaltungs GmbH Hilmar Ingredients IMCD Group BV Ingredion, Inc. Innophos Holdings, Inc. Jrs Pharma GmbH Co. KG Kerry Group plc Roquette Freres S.A. Sensient Pharmaceutical For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Nutraceutical Excipients Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
